©The Author(s) 2026.
World J Gastrointest Oncol. Feb 15, 2026; 18(2): 114690
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114690
Published online Feb 15, 2026. doi: 10.4251/wjgo.v18.i2.114690
Table 4 Comparison of immune function between the two groups before and after treatment, mean ± SD
| Group | Time | CD3+ (%) | CD4+ (%) | CD4+/CD8+ | NK (%) |
| Integration of Chinese and Western medicine group (n = 66) | Before treatment | 58.02 ± 4.48 | 35.01 ± 3.81 | 1.14 ± 0.13 | 5.85 ± 1.57a |
| After treatment | 69.98 ± 8.01a,b | 45.02 ± 3.47a,b | 1.83 ± 0.79a,b | 17.44 ± 3.68a,b | |
| Western medicine group (n = 70) | Before treatment | 58.71 ± 3.45 | 36.31 ± 3.84 | 1.17 ± 0.97 | 7.85 ± 0.97 |
| After treatment | 64.07 ± 4.47a | 38.95 ± 4.57a | 1.48 ± 0.11a | 14.94 ± 0.43a |
- Citation: Wang YR, Wang JQ, Chen XJ, Yan Y, Zhang Y, Li MY, Wang W, Fan TY, Jiao PF, Zhou CF. Efficacy and safety of integrated Chinese and Western medicine in advanced pancreatic cancer: A double-center retrospective cohort study. World J Gastrointest Oncol 2026; 18(2): 114690
- URL: https://www.wjgnet.com/1948-5204/full/v18/i2/114690.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i2.114690